GeoVax (GOVX) Conference Call at 4:30 ET, the 29th.
GeoVax to Host Conference Call at 4:30 PM ET
GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024
ATLANTA, GA, Feb....
GeoVax to Present at the 2024 BIO CEO & Investor Conference
ATLANTA, GA, Feb. 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial!
Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants
We were having cocktails at a fancy restaurant last night with a hedge fund manager, who manages...
GeoVax Labs (GOVX) JP Morgan 2024 Healthcare Conference Transcript.
ILLUSTRATION 3 |MISSION AND STRATEGY
Our mission: One is to innovate. The other one is to differentiate. The other one is to accelerate and finally...
Revive Therapeutics (RVVTF) $0.02, Explores the Use of Bucillamine for Long COVID.
Bucillamine is one of the most amazing drugs (in our opinion), which was repurposed from its original use as an anti-inflammatory for use with...
Adding GeoVax (GOVX) $3.32 to Reverse Stock Split Watch List.
Okay, Here's Our First Name for the Reverse Stock Split, Watch List. We'll Venture to Have 10 Names Added to Watch List Within 30...
Research Report: Society Pass (SOPA) $0.22. Price Target $4.00.
Three New Reports on Society Pass (SOPA) With Price Targets from $3.00 to $4.00.
(All Report Archive)
December 27th, 2023. Litchfield Hills Research – $4.00 Price...
Is David Dodd on to his Next Billion Dollar Payday for Shareholders?
Huge News: Gedeptin® Therapy Demonstrated Safety, Stabilization and Shrinkage of Treated Tumors.
GeoVax (GOVX) Completes Patient Enrollment for Head & Neck Cancer Drug, Gedeptin.®
David...
Citius Pharmaceuticals, Inc. (CTXR) Reports Fiscal Full Year 2023 Financial Results and Provides Business...
Mino-Lok® Pivotal Phase 3 trial enrollment completed; topline data expected 2Q 2024
LYMPHIR™ BLA resubmission on track for early 2024
CRANFORD, N.J., Jan. 2, 2024 /PRNewswire/ -- Citius Pharmaceuticals,...
Adding Geovax (GOVX) to 2024 Biotech Watch List.
GEOVAX (GOVX) $0.32
We added this to the Watch List earlier in the week and then AFTER speaking to CEO David Dodd and the Head...
Latest article
Jeffrey Gundlach: Reckoning is Coming.
Jeffrey Edward Gundlach is a businessman, fund manager, and philanthropist. He is the founder of DoubleLine Capital, an investment firm.
On 11 November 2020, Gundlach remarked in an interview with...
Who’s the Next Eric Sprott?
To say Eric Sprott has left a legendary mark on the world of mining investment would be an understatement. With a career spanning five...
Perpetua (PPTA) Raises $300 Million.
Not a bad day in Idaho. $300 million banked! We look at the dip as a buying opportunity, as does John Paulson & Co.,...
